Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data.
about
Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for TrachomaThe implications of antibiotic resistance for patients' recovery from common infections in the community: a systematic review and meta-analysis.Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium DiseaseRecent Developments in Pediatric Community-Acquired Pneumonia.Variability in Antibiotic Prescribing for Community-Acquired Pneumonia.Macrolide resistance in pneumococci-is it relevant?Comment on: Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data.Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data-authors' resDiagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association.Macrolide-Resistant Pneumococcus in Community-acquired Pneumonia. Is There Still a Role for Macrolide Therapy?Community acquired pneumonia among adult patients at an Egyptian university hospital: bacterial etiology, susceptibility profile and evaluation of the response to initial empiric antibiotic therapy
P2860
Q26777935-D6BA4D3A-6284-43BF-AB73-D2EDE4BFBCA0Q36332161-56C0DE6B-39F2-426F-B188-B2EDC6D82227Q36730088-5C0F5013-0853-4BEC-90FB-CBDA8BEA5EAFQ38767450-B8F350F9-C230-4589-B1F5-900806405E06Q38922276-E5EEB7AF-1146-4564-B06C-CE677258F1E3Q42338498-49BC288D-8AD0-41D3-90D5-F8A2F829508AQ43557285-E89F7A83-717C-4D4F-B22A-D535A6DAD4D7Q43813806-665A5994-1963-46D6-A8EC-64DCCB41FF72Q53516441-98C39AC8-FF3D-48FA-B426-5ACBBFEDEF91Q53840621-5AB7BD97-694A-444D-A5C4-46B481E05B1FQ59135084-155B0F15-A5FB-4FFD-BF41-87DA9E7A68BE
P2860
Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Clinical cure rates in subject ...... f Phase 3 clinical trial data.
@ast
Clinical cure rates in subject ...... f Phase 3 clinical trial data.
@en
type
label
Clinical cure rates in subject ...... f Phase 3 clinical trial data.
@ast
Clinical cure rates in subject ...... f Phase 3 clinical trial data.
@en
prefLabel
Clinical cure rates in subject ...... f Phase 3 clinical trial data.
@ast
Clinical cure rates in subject ...... f Phase 3 clinical trial data.
@en
P2093
P2860
P356
P1476
Clinical cure rates in subject ...... f Phase 3 clinical trial data.
@en
P2093
Cristina Calciu
James A Karlowsky
Karl Weiss
Kevin D Wolter
Patricia Hogan
P2860
P304
P356
10.1093/JAC/DKU207
P407
P577
2014-06-11T00:00:00Z